Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bydureon vs Placebo for 24-hour Glucose Control in T2DM
NCT02288273Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2014
- Primary completion
- Aug 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Bydureon with Placebo (2 arms). Primary endpoint: Change in 24-hour Mean Weighted Glucose at Day 28. Started Dec 2014; status: completed.
02
Drugs
exenatide extended-release
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02288273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02288273.